Euglycemic diabetic ketoacidosis associated with a sodium-glucose co transporter 2 inhibitor use in a trauma patient: a case report

Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i), like empagliflozin, are widely prescribed for managing type 2 diabetes mellitus. However, they carry a rare but serious risk: euglycemic diabetic ketoacidosis (EDKA). EDKA’s atypical presentation, characterized by metabolic aci...

Full description

Bibliographic Details
Published in:	International Journal of Emergency Medicine
Main Authors:	Ophélie Dirand, Julie Dupont, Emmanuel Weiss, Myriam Lamamri
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Trauma Euglycemic diabetic ketoacidosis Sodium-glucose co transporter 2 inhibitors Sepsis shock
Online Access:	https://doi.org/10.1186/s12245-025-00963-8

Similar Items

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
by: Alexis Diaz-Ramos, et al.
Published: (2019-09-01)

Euglycemic diabetic ketoacidosis reported in pregnant women
by: Balasubramaniam Branavan, et al.
Published: (2019-12-01)

A case report of euglycemic ketoacidosis due to dapagliflozin treatment
by: Murat Çalapkulu, et al.
Published: (2021-03-01)

A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?
by: Shushmita Hoque, et al.
Published: (2025-07-01)

Euglycemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors after surgery: A case report and review of literature
by: Mei-An Pai, et al.
Published: (2023-01-01)

Factors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study
by: Miho Takemura, et al.
Published: (2025-08-01)

Euglycemic diabetic ketoacidosis and COVID‐19 management in a term pregnant patient; a case report
by: Fatemeh Mohammadzade, et al.
Published: (2022-12-01)

How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review
by: Carolina Bologna, et al.
Published: (2025-10-01)

Euglycemic Ketoacidosis in a non-diabetic patient: a rare adverse effect of sodium-glucose co-transporter type-2 inhibitors. A review based on a case report
by: Francisca Fonseca, et al.
Published: (2025-01-01)

Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
by: Joanna Winciorek, et al.
Published: (2024-09-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

The significance of precise diabetes diagnosis: a case of euglycemic diabetic ketoacidosis induced by the introduction of empagliflozin with simultaneous reduction of insulin dosage
by: Wiktoria Bińczyk, et al.
Published: (2024-05-01)

Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report
by: Lulu Chu, et al.
Published: (2025-01-01)

Acute pancreatitis and euglycemic non-diabetic ketoacidosis caused by an intentional semaglutide overdose
by: Anthony Acosta, et al.
Published: (2025-03-01)

Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
by: Siddhartha Dutta, et al.
Published: (2022-01-01)

Can euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors be avoided in COVID-19 and other acute infections?
by: Georgios Pilianidis, et al.
Published: (2024-02-01)

Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis
by: Siti Sanaa Wan Azman, et al.
Published: (2022-05-01)

Euglycemic diabetic ketoacidosis associated with empagliflozin in patients hospitalized with acute pulmonary embolism
by: Kevin Wibawa, et al.
Published: (2021-05-01)

Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review
by: Erasmia Sampani, et al.
Published: (2020-07-01)

SGLT-2 inhibitor–associated significant hypernatremia and euglycemic diabetic ketoacidosis after cardiac surgery: a case series
by: En-ze Bian, et al.
Published: (2026-04-01)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Managing Hospitalized Patients Taking SGLT2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis
by: Julia Selwyn, et al.
Published: (2023-02-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

Euglycemic diabetic ketoacidosis development in a patient with type 2 diabetes receiving a sodium-glucose cotransporter-2 inhibitor and a carbohydrate-restricted diet
by: Gwanpyo Koh, et al.
Published: (2023-09-01)

Re-emergence of a forgotten diabetes complication: Euglycemic diabetic ketoacidosis
by: Murat Dagdeviren, et al.
Published: (2024-01-01)

Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic
by: Nicholas Arlas, et al.
Published: (2022-03-01)

Diabetic Ketoacidosis Management: Updates and Challenges for Specific Patient Population
by: Azza B. El-Remessy
Published: (2022-12-01)

Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01)

Acute effects of euglycemic‐hyperinsulinemia on myocardial contractility in male mice
by: Satya Murthy Tadinada, et al.
Published: (2022-09-01)

SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series
by: Wei Qiang, et al.
Published: (2024-09-01)

Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report
by: Venkata Vinod Kumar Matli, et al.
Published: (2021-12-01)

Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report
by: Agnieszka Gandecka-Pempera, et al.
Published: (2025-10-01)

The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study
by: Yudai Iwasaki, et al.
Published: (2022-08-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors
by: Elsayed Balbaa, et al.
Published: (2026-03-01)

To Evaluate the Effect of Edrophonium on Blood Glucose Levels in Euglycemic Albino Rats Through OGTT
by: Siddamma Amoghimath, et al.
Published: (2015-01-01)

Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights
by: Han-Sang Baek, et al.
Published: (2024-11-01)

Euglycemic diabetic ketoacidosis in type 2-diabetes mellitus treated with SGLT2 inhibitors - a report on two cases
by: Antonio Burgio, et al.
Published: (2018-11-01)

Euglycemic diabetic ketoacidosis due to small bowel perforation: a case report
by: Lorenzo Fornaciari, et al.
Published: (2024-06-01)

Diabetic Ketoacidosis in Young Adults with Type 1 Diabetes: The Impact of the Ketogenic Diet—A Narrative Literature Review
by: Joanna Cielecka, et al.
Published: (2025-10-01)